Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C16H20N2O2.C4H6O6 |
| Molecular Weight | 694.7712 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCN(C)C(=O)OC1=CC=C2CC[C@@H](NCC#C)C2=C1.CCN(C)C(=O)OC3=CC=C4CC[C@@H](NCC#C)C4=C3
InChI
InChIKey=PRLVBVAJMQZMJN-OGOSNNLPSA-N
InChI=1S/2C16H20N2O2.C4H6O6/c2*1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2;5-1(3(7)8)2(6)4(9)10/h2*1,6,8,11,15,17H,5,7,9-10H2,2-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*15-;1-,2-/m111/s1
| Molecular Formula | C16H20N2O2 |
| Molecular Weight | 272.3422 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C4H6O6 |
| Molecular Weight | 150.0868 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
LADOSTIGIL, a rasagiline derivative, is a reversible acetylcholinesterase and butyrylcholinesterase inhibitor with neuroprotective properties. It also acts as an irreversible brain monoamine oxidases inhibitor. It is under development for the treatment of neurodegenerative disorders like dementia and Alzheimer's disease.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents. | 2010-06 |
|
| The role of rasagiline in the treatment of Parkinson's disease. | 2010-05-25 |
|
| The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis. | 2010 |
|
| Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk. | 2009-12-01 |
|
| Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons. | 2009-08-12 |
|
| Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? | 2009-04-02 |
|
| The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. | 2009-02 |
|
| Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. | 2009-01 |
|
| The neurotrophic and neuroprotective effects of psychotropic agents. | 2009 |
|
| The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. | 2008-09-25 |
|
| The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats. | 2008-08 |
|
| The neuroprotective mechanism of action of the multimodal drug ladostigil. | 2008-05-01 |
|
| Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. | 2007-12 |
|
| Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. | 2007-10 |
|
| Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil. | 2007-08 |
|
| Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. | 2007-03 |
|
| The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection. | 2007-02 |
|
| Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. | 2006-12 |
|
| The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. | 2006-12 |
|
| A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. | 2006-10 |
|
| Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression. | 2006 |
|
| The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. | 2005-10 |
|
| Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats. | 2005-08 |
|
| Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. | 2005-02 |
|
| Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. | 2004-12-02 |
|
| Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. | 2004-03-25 |
|
| Protein 4.1N is required for translocation of inositol 1,4,5-trisphosphate receptor type 1 to the basolateral membrane domain in polarized Madin-Darby canine kidney cells. | 2003-02-07 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:59 GMT 2025
by
admin
on
Mon Mar 31 18:05:59 GMT 2025
|
| Record UNII |
2J1346C51H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
|
||
|
NCI_THESAURUS |
C667
Created by
admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000044446
Created by
admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
|
PRIMARY | |||
|
CHEMBL255231
Created by
admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
|
PRIMARY | |||
|
209394-46-7
Created by
admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
|
PRIMARY | |||
|
C76072
Created by
admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
|
PRIMARY | |||
|
QQ-52
Created by
admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
|
PRIMARY | |||
|
2J1346C51H
Created by
admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
|
PRIMARY | |||
|
11607225
Created by
admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
|
PRIMARY | |||
|
DTXSID60175107
Created by
admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |